Whether or not the interval between injections of Tirelizumab can exceed 21 days needs to be determined based on the actual condition, medication use, individual status and other factors. Generally, the recommended dosing schedule for this drug is every 21 days, but not all patients need to take the drug at this time, and if it is determined that the patient can take the drug at longer intervals after careful diagnosis by the doctor, the drug can be taken for more than 21 days. This drug is indicated for patients with relapsed or refractory classical Hodgkin lymphoma who have previously undergone second-line systemic chemotherapy. Common adverse reactions include respiratory infections, anemia, neutropenia, leukopenia, abnormal thyroid function, loss of appetite, and insomnia. The drug is not recommended for lactating and pregnant women, and those who are allergic to this drug need to disable it. The drug must be used under the guidance of a professional oncologist.